Crinetics Pharmaceuticals, Inc.
CRNXDelisted Sep 1, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658247
Crinetics Pharmaceuticals, Inc. was delisted on Sep 1, 2026; its insiders filed their last Form 4 on Sep 1, 2026; 267 institutions reported holding it in 13F filings for Q2 2026, worth $4.63B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Crinetics Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $120.0K in total
- Insiders trading
- 1
- Net value
- −$120.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Crinetics Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wierenga Wendell | Director | 0 | Sep 1, 2026 | 2 |
| Vivaldi Coelho Rogerio | Director | 0 | Sep 1, 2026 | 4 |
| Okey Stephanie | Director | 0 | Sep 1, 2026 | 4 |
| Nichols Weston | Director | 0 | Sep 1, 2026 | 2 |
| Fust Matthew K | Director | 0 | Sep 1, 2026 | 3 |
| Deardorf Caren | Director | 0 | Sep 1, 2026 | 2 |
| Bedrosian Camille L | Director | 0 | Sep 1, 2026 | 2 |
| Kalofonos Isabel | Chief Commercial Officer | 0 | Sep 1, 2026 | 3 |
| Betz Stephen F. | Chief Scientific Officer | 0 | Sep 1, 2026 | 4 |
| Schilke Tobin | Chief Financial & Infra. Ofcr. | 0 | Sep 1, 2026 | 4 |
| Struthers Richard Scott | President & CEO | 0 | Sep 1, 2026 | 7 |
| Knight Jeff E. | Chief Dev. & Operating Officer | 105,289 | Apr 10, 2026 | 3 |
| Pizzuti Dana | Chief Med and Dev Officer | 66,837 | Dec 3, 2025 | 3 |
| Wierenga Wendall | Director | 116,146 | Jun 13, 2025 | 0 |
| Wilson Marc | CFO | 111,092 | Sep 30, 2024 | 0 |
| Hassard James | Chief Commercial Officer | 29,259 | Jul 9, 2024 | 0 |
| Krasner Alan Seth | Chief Medical Officer | 43,210 | Oct 19, 2023 | 0 |
| Edelman Joseph | 10% Owner | 5,321,032Indirect | Apr 18, 2022 | 0 |
| Perceptive Advisors LLC | 10% Owner | 5,321,032Indirect | Apr 18, 2022 | 0 |
| Perceptive Life Sciences Master Fund Ltd | 10% Owner | 5,321,032Indirect | Apr 18, 2022 | 0 |
| Madan Ajay | Chief Development Officer | 176,995 | Mar 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2025 (view filing) | Aug 20 | 1 day | Pizzuti DanaChief Med and Dev Officer | SSale | −6.49K | $29.18 | −$189.4K | −8.9%66.3K after | 10b5-1 |
| Aug 26, 2025 (view filing) | Aug 22 | 4 days | Pizzuti DanaChief Med and Dev Officer | SSale | −30.0K | $30.43 | −$912.9K | −31.2%66.3K after | 10b5-1 |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Pizzuti DanaChief Med and Dev Officer | SSale | −5.00K | $32.10 | −$160.5K | −4.9%96.3K after | 10b5-1 |
| Sep 30, 2025 (view filing) | Sep 26 | 4 days | Fust Matthew KDirector | SSale | −16.0K | $44.75 | −$716.0K | −41.2%22.8K after | 10b5-1 |
| Sep 30, 2025 (view filing) | Sep 26 | 4 days | Struthers Richard ScottPresident & CEO | SSale | −4.00K | $45.00 | −$180.0K | −3.6%106.0K after | 10b5-1 |
| Oct 3, 2025 (view filing) | Oct 1 | 2 days | Pizzuti DanaChief Med and Dev Officer | SSale | −5.00K | $41.81 | −$209.1K | −7.0%66.3K after | 10b5-1 |
| Nov 5, 2025 (view filing) | Nov 3 | 2 days | Pizzuti DanaChief Med and Dev Officer | SSale | −5.00K | $42.66 | −$213.3K | −7.0%66.3K after | 2 lots10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Pizzuti DanaChief Med and Dev Officer | SSale | −5.00K | $45.02 | −$225.1K | −7.0%66.8K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Kalofonos IsabelChief Commercial Officer | SSale | −2.50K | $55.00 | −$137.5K | −75.0%834 after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Schilke TobinChief Financial Officer | SSale | −6.71K | $39.67 | −$266.3K | −7.9%78.1K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Okey StephanieDirector | SSale | −3.00K | $39.67 | −$119.0K | −18.4%13.3K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Vivaldi Coelho RogerioDirector | SSale | −5.00K | $36.15 | −$180.8K | −23.5%16.3K after | 2 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Struthers Richard ScottPresident & CEO | SSale | −22.0K | $37.37 | −$821.5K | −5.2%404.8K after | 2 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −10.6K | $37.37 | −$396.6K | −7.2%137.1K after | 2 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Knight Jeff E.Chief Operating Officer | SSale | −9.91K | $37.37 | −$370.4K | −8.1%112.0K after | 2 lots10b5-1 |
| Apr 10, 2026 (view filing) | Apr 8 | 2 days | Knight Jeff E.Chief Dev. & Operating Officer | SSale | −85.2K | $40.10 | −$3.42M | −44.7%105.3K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Okey StephanieDirector | SSale | −6.90K | $35.67 | −$246.1K | −51.9%6.40K after | 2 lots10b5-1 |
| Jul 7, 2026 (view filing)4:30 PM ET | Jul 2 | 5 days | Vivaldi Coelho RogerioDirector | SSale | −3.00K | $40.00 | −$120.0K | −13.5%19.2K after | 10b5-1 |